Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
Summary
BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the completion of an $85 million financing. That combined capability and the multiplexing opportunities it enables are unprecedented and position Engenious as a best-in-class engineered cell therapy platform,” said Emile Nuwaysir, Ph.D., president and chief executive officer of Ensoma. With support from the Creation House program sponsored by the BioInnovation Institute in Copenhagen and seed investment from Arix Bioscience, Twelve Bio has advanced foundational insights from X-ray crystallography and cryogenic electron microscopy to further engineer and evolve CRISPR-Cas12a into wholly novel sequences with unique properties useful for a range of DNA editing strategies. At Twelve Bio, we have developed innovative gene editing tools that can correct sequences linked to genetic disorders, and Ensoma is a world-leading company for in vivo delivery to hemopoietic stem cells. Engenious is based on over two decades of academic and clinical research generated by its scientific co-founders and renowned experts Hans-Peter Kiem, M.D., Ph.D., of Fred Hutchinson Cancer Center, and André Lieber, M.D., Ph.D., of University of Washington School of Medicine.